Close Menu

NEW YORK (GenomeWeb) — The American Cancer Society's (ACS) newly formed philanthropic fund BrightEdge has made its first investment, contributing $3 million to Castle Biosciences' $11.6 million convertible note financing last month, the organizations said on Thursday.

BrightEdge, headquartered in Atlanta, was founded by the ACS to invest in for-profit companies developing novel cancer therapeutics and diagnostics. It was established with a $25 million commitment from ACS and aims to raise an additional $100 million from private donors.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.